Boehringer Ingelheim GmbH - R&D Services

Boehringer Ingelheim GmbH
Research and Development is Boehringer Ingelheim's driving force
For a global player in the pharmaceutical industry it is no longer sufficient to develop drugs that simply match products already on the market. As a research-driven pharmaceutical group of companies, Boehringer Ingelheim is committed to the goal of discovering and developing Products which represent high therapeutic value for patients, the physician and health care providers. This is achieved by first class research and development for which the Boehringer Ingelheim group of companies spent EUR 1,232 million in 2004.
Front-line research and development projects are the means by which therapeutic goals are achieved. Demonstrating its commitment to innovation, Boehringer Ingelheim's
R & D expenditure was 15.3 per cent of net sales in 2004.
A string of new medicinal products has been the result of the corporation's efforts. These steps forward in therapeutic benefit have come from Boehringer Ingelheim's own research. Prominent among the more recent therapies discovered and developed in-house are within the field of treatment of chronic obstructive pulmonary disease (COPD), for essential Hypertension, and for the treatment of HIV-1 infection.
Clinical development and registration at Boehringer Ingelheim are an essential part of bringing Research & Development results to the market.
Boehringer Ingelheim strives to contribute with its Research & Development to a better and healthier world.
Boehringer Ingelheim GmbH
Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany
Phone +49/6132/77 0
Fax +49/6132/72 0